A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

This study is testing a cancer vaccine called PVX7 in women who have completed primary treatment for advanced cervical cancer (stages IB1 through IVA) and are currently in remission. The goal is to see if this immunotherapy approach can help the immune system recognize and prevent cancer from coming back. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with advanced cervical cancer (stage IB1–IVA) and completed primary treatment (surgery, radiation, and/or platinum-based chemotherapy) within the past 12 months - You currently show no evidence of remaining or returning cancer on imaging and clinical assessment - You may also be receiving or recommended to receive anti-PD-1/PD-L1 immunotherapy, which can continue during this study - You are HIV-negative, Hepatitis B surface antigen-negative, and Hepatitis C-negative **You may NOT be eligible if...** - You have evidence of remaining or recurrent cancer - You are HIV-positive or have active hepatitis B or C infection - You have received the study drug previously or do not meet safety criteria for immunotherapy Talk to your doctor to see if this trial is right for you.